Abstract 41P
Background
Triple-negative breast cancer (TNBC) is associated with more aggressive disease and worse survival compared to other breast cancer subtypes. We aim to analyze the role of oncogenic mir-223 as a possible negative driving factor in TNBC through its prognostic value and association with unfavorable clinicopathologic characteristic.
Methods
We retrospectively analyzed the association of pre-treatment mir-223 expression with clinicopathologic characteristics and 3-years overall survival (OS) of Indonesian TNBC patients treated in a tertiary center during 2014-2017. Cytokeratin5/6 (CK5/6) and Epidermal Growth Factor Receptor (EGFR) expressions were examined using immunohistochemistry by 2 independent blinded pathologists. Mir-223 level of tumor tissue was measured using Real-Time qRT-PCR. Cutoff value for mir-223 was determined using Receiver Operating Curve (ROC). Chi-square and Fisher’s exact tests were used to analyze the association between categorical variables, while Kaplan-Meier curve was used to perform survival analysis.
Results
Fifty-three stage I-IV TNBC patients were included in the analysis. The mean age of our patients was 51.3 years old. Early stage, locally advanced stage, and metastatic disease respectively were found in 7 (13.2%), 38 (71.7%), and 8 (15.1%) patients. The optimal cutoff value for mir-223 was 23.435 (AUC: 0.706, 95%CI: 0.565-0.848; p: 0.01; Sensitivity: 78.6%; Specificity: 56%) and was used to classify mir-223 expression into over- and under-expressed groups. Mir-223 overexpression was associated with increased expression of EGFR (69.7% vs. 35%, p: 0.022) and lower 3-years OS (33.3% vs. 70%; mean OS±SE (months): 25.66±1.58 vs. 30.23±1.99; p log rank: 0.029). No significant association was observed between mir-223 expression with other clinicopathologic characteristics (age, BMI, stage, tumor size, nodal status, distant metastasis, and CK5/6 expression).
Conclusions
Pre-treatment mir-223 level of expression in Indonesian TNBC patients is correlated with poor survival through increase of EGFR expression. Thus, targeting mir-223 becomes a potential therapeutic strategy for TNBC patients. However, further study is needed to validate this result.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
67TiP - HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
Presenter: Norikazu Masuda
Session: e-Poster Display Session
68TiP - KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Presenter: Shigehira Saji
Session: e-Poster Display Session
69TiP - MADELINE Asia: A mobile app-based prospective observational study of patient reported outcomes in advanced breast cancer in Asia
Presenter: Anna Tai
Session: e-Poster Display Session
113TiP - Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan
Presenter: Hiroki Yukami
Session: e-Poster Display Session
195TiP - GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Rui-Hua Xu
Session: e-Poster Display Session
196TiP - Perioperative sintilimab in combination with concurrent chemoradiotherapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Jia Wei
Session: e-Poster Display Session
197TiP - A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Presenter: Shukui Qin
Session: e-Poster Display Session
198TiP - SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Kohei Shitara
Session: e-Poster Display Session
233TiP - Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study
Presenter: Daniel Petrylak
Session: e-Poster Display Session
254TiP - ENGOT-cx11/KEYNOTE-A18: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab With Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer
Presenter: Domenica Lorusso
Session: e-Poster Display Session